牛牛AI助手已提取核心信息
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced its unaudited preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made in conjunction with the company's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Illumina reported a consolidated revenue of approximately $1,115 million for Q4 2023, marking a 3% increase from Q4 2022, and a total revenue of approximately $4,497 million for the fiscal year 2023, which is a 2% decrease from the previous year. The company's core revenue also saw a 2% increase in Q4 2023 compared to the same quarter in the previous year, but experienced a 3% decline for the full fiscal year. Illumina shipped a total of 79 NovaSeq X instruments in Q4 and 352 for the...Show More
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced its unaudited preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made in conjunction with the company's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Illumina reported a consolidated revenue of approximately $1,115 million for Q4 2023, marking a 3% increase from Q4 2022, and a total revenue of approximately $4,497 million for the fiscal year 2023, which is a 2% decrease from the previous year. The company's core revenue also saw a 2% increase in Q4 2023 compared to the same quarter in the previous year, but experienced a 3% decline for the full fiscal year. Illumina shipped a total of 79 NovaSeq X instruments in Q4 and 352 for the entire year. The GAAP operating margin for Q4 was reported at approximately (15.5%) and (24.0%) for the fiscal year, while non-GAAP operating margins were 3.8% for Q4 and 5.3% for the fiscal year. Core Illumina's GAAP operating margin stood at 2.4% for Q4 and 12.3% for the fiscal year, with non-GAAP operating margins at 18.0% for Q4 and 19.8% for the fiscal year. The company plans to report its full fourth quarter and fiscal year 2023 results on February 8, 2024, after market close. The preliminary results are subject to the completion of accounting and annual audit procedures and may be adjusted.
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 公布了截至2023年12月31日的第四季度和财年未经审计的初步财务业绩。该公告是在公司于2024年1月9日参加第42届摩根大通医疗保健年度会议时发布的。Illumina报告称，2023年第四季度的合并收入约为11.15亿美元，较2022年第四季度增长3％，2023财年的总收入约为44.97亿美元，比上年下降2％。与去年同期相比，该公司的核心收入在2023年第四季度也增长了2％，但整个财年下降了3％。Illumina在第四季度共出货了79台NovaSeq X仪器，全年共出货了352台仪器。据报告，第四季度的GAAP营业利润率...展开全部
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 公布了截至2023年12月31日的第四季度和财年未经审计的初步财务业绩。该公告是在公司于2024年1月9日参加第42届摩根大通医疗保健年度会议时发布的。Illumina报告称，2023年第四季度的合并收入约为11.15亿美元，较2022年第四季度增长3％，2023财年的总收入约为44.97亿美元，比上年下降2％。与去年同期相比，该公司的核心收入在2023年第四季度也增长了2％，但整个财年下降了3％。Illumina在第四季度共出货了79台NovaSeq X仪器，全年共出货了352台仪器。据报告，第四季度的GAAP营业利润率约为（15.5％）和（24.0％），而第四季度的非GAAP营业利润率为3.8％，该财年的5.3％。Core Illumina第四季度的GAAP营业利润率为2.4％，本财年的营业利润率为12.3％，第四季度的非公认会计准则营业利润率为18.0％，该财年的19.8％。该公司计划在市场收盘后于2024年2月8日公布其第四季度和2023财年的完整业绩。初步结果视会计和年度审计程序的完成而定，并可能进行调整。
有用
没用